Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
April 27, 2009
- Majority of Major Drug Firms Increase Hiring of New Graduates in 2009
April 27, 2009
- Coefficients for Generics for DPC Hospitals May Be Introduced
April 27, 2009
- Yokohama Clinic Starts Cancer Therapy Using Dendritic Cells
April 27, 2009
- PMDA Creates New Office to Review Anticancer Drugs
April 27, 2009
- Asahi Kasei Licenses Flivas to Dong-A
April 27, 2009
- BUSINESS NEWS IN BRIEF
April 27, 2009
- Otsuka Aims at Further Growth Driven by Its Own Products in Oncology, CNS
April 27, 2009
- Drug Market in China to Reach US$50 Bil. in 2012
April 27, 2009
- Kowa, Apo Plus Station Creates "Career & Leaps" to Support Marketing of OTC Drugs
April 20, 2009
- Kissei's Urief Launched in the US
April 20, 2009
- Alpha MOS Sets Up Japanese Subsidiary
April 20, 2009
- Daiichi Sankyo, Eli Lilly Launch Prasugrel in UK
April 20, 2009
- Takara Bio Obtains License from Kyoto Univ.
April 20, 2009
- Eli Lilly Licenses Cialis to Nippon Shinyaku
April 20, 2009
- GE, Intel Ally in Home Health Technologies
April 20, 2009
- Otsuka, BMS Extend Agreement on Abilify, Embark on Global Oncology Collaboration
April 20, 2009
- Olympus Releases Biliary Stent Jointly with Medinol
April 20, 2009
- Pfizer Aims to Become Market Leader for Macrolides with Zithromac SR
April 20, 2009
- AMDD Inaugurated with Dr H. Wang as President
April 20, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…